Search

Author Index

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

 

E
Earp S. - Deficiency in one Gas6 receptor (Axl, Sky or Mer) protects mice against thrombosis because of a platelet dysfunction
Earp B. - Reliability of patient self-testing and point-of-care testing with the Harmony (TM) INR monitoring system: a 3-year study
Eastvold J. S. - Role of the FcR gamma chain in collagen-induced platelet procoagulant activity
Ebbesen L. S. - Hyperhomocysteinemia (HH) down regulates thrombin generation. FII:C, FXII:C and FX:C are down-regulated in HH while FVII:C is unaffected by HH
Ebbesen L. S. - Whole blood coagulation profiles in patients with thrombosis
Eberl W. - Mutation profiling in congenital FXIIIA deficiency: detection of 6 novel mutations
  - Mutations in genes of the gamma-glutamyl carboxylase and the vitamin K epoxidase reductase complex are responsible for the phenotype of hereditary combined deficiency of vitamin K-dependent clotting factors
Ebert D. D. - A case of compound type 2N/type 1 von Willebrand disease linked to a novel von Willebrand factor exon 18 mutation A2311G encoding for Met 771 val
Eckes B. - Normal arterial thrombus formation in integrin a2-deficient mice
Eckly A. - Evidence for a PLCg2-independent alpha2beta1-triggered signalling pathway contributing to platelet aggregation in response to collagen
  - PLC g-dependent GPIb signaling following platelet adhesion to von Willebrand factor through a pathway distinct from FcR g chain and FcgRIIA
Edelberg J. - EPC restoration of cardio protection for the aging heart
Edelev D. - Influence of peloidotherapy on hemostasis, cytokines productions and lymphocyte-platelet adhesion
Edgell D. - Frequency and predictors of vaso-occlusive strokes associated with cardiac surgery in infants and children with congenital heart disease
Edwards R. J. - Identification of an integrin-associated chloride channel in human platelets
Efimov V. S. - The role of thrombophilias in the origin of cerebrovascular accidents at the patients with Atrial Fibrillation
Egberts J. F. M. - Fondaparinux vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients (artemis)
Egglezou S. - Development of bifunctional inhibitors of both platelet aggregation and factor Xa
Eguchi Y. - Different distribution of antithrombin and thrombomodulin in endotoxin-treated rat: effect of antithrombin and activated protein c concentrates and nafamostat mesilate
Ehl S. - Insufficient F IX-recovery after treatment with recombinant F IX compared to plasma-derived F IX
Ehrlich Y. H. - Phosphorylation and expression of the extracellular domain of the platelet adhesion receptor, F11R (a.k.a. junctional adhesion molecule, JAM-1)
  - Genomic structure, organization and promoter analysis of the human F11 receptor (F11R) (junctional adhesion molecule-1, JAM-1)
  - The platelet adhesion receptor, F11R (a.k.a. JAM-1), is critical for the initiation of plaque formation, thrombosis and atherosclerosis
Eich S. - The thrombogenic agent in prothrombin complex concentrates (PCC): Identification of elevated levels of prothrombin as the major cause
Eichinger S. - Assessing the risk of recurrence in patients with a first spontaneous venous thromboembolism by use of D-dimer
Eichinger S. - C-reactive protein in patients with venous thromboembolism
  - Homocysteine lowering by B vitamins and the prevention of secondary deep-vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial
Eichler P. - Cross-reactivity of anti-lepirudin antibodies from patients with heparin-induced thrombocytopenia with bivalirudin
Eichler P. - The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study
  - Anaphylactic reactions associated with lepirudin in patients with heparin-induced thrombocytopenia (HIT)
  - Benefit and risk of heparin addition in maintaining peripheral venous catheters in neonates – a prospective, double-blind, placebo-controlled trial
Eifrig B. - The development of inhibitors directed against factor VIII after continuous infusion of factor VIII concentrates in patients with hemophilia A
Eigenbrot C. - Differential use of variable domains of D3H44 antibody in binding to tissue factor or to an anti-idiotypic antibody
  - Similar molecular interactions of factor VII and factor VIIa with the tissue factor region that allosterically regulates enzyme activity
Eigenthaler M. - Platelet activation and platelet VASP phosphorylation in mice with streptozotocin-induced diabetes mellitus – association with endothelial dysfunction and reduced nitric oxide bioactivity
  - Inhibition of platelet activation in congestive heart failure by selective aldosterone receptor antagonism and angiotensin-converting enzyme inhibition – role of platelet VASP phosphorylation
Eigenthaler M. - Activated platelets induce migration, proliferation and gene expression in human vascular endothelial cells
Eigenthaler M. - Biphasic human platelet response to cGMP mediated via distinct signaling pathways: a predominant role for cAMP-dependent protein kinase in the cGMP-induced platelet inhibition and phosphorylation of vasodilator-stimulated phosphoprotein
Eigenthaler M. - The molecular mechanisms of platelet activation by prolactin
  - cGMP regulates thrombopoietin-induced CD34+ human stem cell proliferation and differentiation into megakaryocytes
Eigenthaler M. - Novel role for the membrane-bound chemokine fractalkine as a pathophysiologically relevant mechanism in platelet activation and adhesion
  - Interest of VASP measurement on patients treated by thienopyridines
Eikelboom J. W. - Anti-phospholipid antibodies in ischemic stroke
Eikelboom J. - Normal platelet-poor plasma correction studies in the laboratory diagnosis of lupus anticoagulant
Eikelboom J. W. - Low-molecular-weight heparin is as effective and safe as unfractionated heparin for the initial treatment of pulmonary embolism: a meta-analysis
Eikenboom J. C. M. - Evaluation of a new quantitative, rapid test (VWF-LIA) for the diagnosis of type 1 VWD
  - Sensitivity and specificity of PFA-100® vs. bleeding time in the diagnosis of type 1 von Willebrand disease (VWD)
Eikenboom J. - Molecular and clinical markers for the diagnosis and management of type 1 von Willebrand's disease (VWD): The progress of a European collaboration
  - Mutation analysis in type 1 von Willebrand disease patients entered in the multicenter MCMDM-1VWD study
Eikenboom J. C. J. - An improved multimeric analysis identifies a subgroup of patients with Type 1 von Willebrand disease characterized by reduced VWF:RCo/Ag ratio
  - Comparison of hemorrhagic symptoms in obligatory carriers of type 1 and type 3 von willebrand disease (VWD): results from a collaborative, international, multicenter study
Eikenboom J. C. J. - Co-segregation of Von Willebrands disease type 1 phenotype and Von Willebrand factor gene haplotypes: first results from the multicenter study molecular and clinical markers for the diagnosis and management of type 1 Von Willebrands disease
Eikenboom J. J. - In vitro expression of 4 novel mutations identified in type 1 von Willebrand disease patients
Eikenboom J. C. J. - Clinical presentation of type 1 von Willebrand disease (VWD) in obligatory carriers: final results from a collaborative, international, multicenter study
  - Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues
Eilertsen K. - Association of the -159 C-to-T polymorphism in the CD14 promoter with variations in serum lipoproteins in healthy subjects
Eilertsen K. E. - The relationship between sh-CRP and reactivity of monocytes and various blood parameters known to play an important role in atherogenesis
Eilertsen K. - The effect of peroxisome proliferator-activated receptor a and g activators on lipopolysaccharide-induced monocyte tissue factor activity and TNFa in human whole blood
Einarson T. - Final results from the Canadian hemophilia dose escalation prophylaxis trial
Eisbacher M. - Protein–protein interaction between Fli-1 and GATA-1 mediates synergistic expression of megakaryocyte-specific genes through cooperative DNA-binding
Eisele R. R. - Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery
Eisele R. - PTS after calf vein thrombosis (CVT): a 10-year follow-up
Eisert R. - New mutations in the fibrinogen genes of patients with dys, hypo- or fibrinogenemia
Eitzman D. - Development of small molecule compounds that inhibit PAI-1 activity in vitro and in vivo
Eitzman D. T. - The factor V Leiden mutation results in the in vivo loss of a critical FV anticoagulant function
El Ali M. - C-reactive protein: a link between inflammation and thrombosis formation in patients with unstable angina?
El Bedoui J. - Thrombin induces the expression of pro-MMP-2 and its conversion to MMP-2 in vascular smooth muscle cells: both responses are inhibited by red wine polyphenols
El Khafif N. - Ultrastructural changes in platelets after surgical manipulations in pigs liver
El Kheir D. - Comparison of 2 d-dimer assays (MDA®d-dimer and Tina-quant®d-dimer) in patients with suspected recurrent deep venous thrombosis – an interim analysis
El Rouby S. - Safety of low intensity warfarin regimen in Chinese patients With mechanical heart valve prostheses
El Rouby S. - A novel recombinant tissue factor assay for measuring the anti-Xa effect of Low-Molecular-Weight Heparin (LMWH): implications for interventional coronary procedures
Elalamy I. - The role of tissue factor on the inhibition of prothrombin activation and thrombin generation by the synthetic pentasaccharide (fondaparinux)
  - Effect of rFVIIa (NovSeven®) on thrombin generation in patients with severe thrombocytopenia
  - The role of tissue factor on the inhibition of prothrombin activation and thrombin generation by the synthetic pentasaccharide (fondaparinux)
  - Effect of Fondaparinux on clot formation after tissue factor pathway activation. A thromboelastography study
  - Risk of pregnancy-related venous thromboembolism (VTE) in 60 hereditary AT-deficient women from 45 families: study of 164 pregnancies
Elbaz O. - Elevated Serum Nerve Growth Factor (NGF) levels in patients with acute leukemia and lymphoma especially with CNS involvement
  - Isolated thrombocytopenia as a preliminary feature of antiphospholipid syndrome in patients with chronic liver disease
Elchaninov A. P. - Interaction between prothrombotic polymorphisms and lupus anticoagulant in chronic cerebrovascular disease
El-Deib A. - Tissue factor and tissue factor pathway-inhibitor in chronic hepatitis C patients
Elder P. A. - Plasma adiponectin and the metabolic syndrome
Eldibany M. - Use of umbilical cord vein in an in vitro perfusion model to study blood-borne metastasis
Eldridge J. - The relationship between the TNF-308 polymorphism and Legg-Perthes disease
El-Gamal S. - Isolated thrombocytopenia as a preliminary feature of antiphospholipid syndrome in patients with chronic liver disease
Eligini S. - Reactive oxygen species mediate cyclooxygenase-2 induction during monocyte transition into macrophages: critical role for NADPH oxidase
Eljaafari A. - In vitro flow cytometry and functional testing of fresh and cryopreserved platelets
El-Jamil M. - The relationship between the TNF-308 polymorphism and Legg-Perthes disease
Elkum N. - Single center review of clinicopathological characterization in 77 patients with positive lupus anticoagulant antibodies
Ellingsen D. - Relationship of the Val34Leu polymorphism in the factor XIII gene with venous thromboembolism in American whites and blacks: the GATE study
Ellis V. - The prion protein as a regulator of tPA activity
Ellis M. - Efficacy and safety of two doses of enoxaparin in pregnant women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study
El-Maarri O. - Analysis of mRNA in a panel of hemophilia A patients with no detectable mutation in the coding regions of the factor VIII gene
El-Omar M. M. - CD39 ecto-nucleotidase activity (metabolizing ATP to ADP to AMP) constitutes a homeostatic mechanism for control of platelet reactivity, depending on the ratio of ADPase to ATPase activity. Results from patients with coronary artery disease
Elvevoll E. O. - The relationship between sh-CRP and reactivity of monocytes and various blood parameters known to play an important role in atherogenesis
Elwin C.-E. - Effects of three low doses of aspirin on thromboxane synthesis in platelets and on bleeding time – a comparative study
Emekli N. - Effects of 6,7-dihydroxy-3-phenylcoumarin and warfarin on thromboplastin induced experimental disseminated intravascular coagulation
Emerson D. - Effect of short-term, low-fat vegetarian diet and walking program on coagulation
Emiliani C. - Lysosomal beta-N-acetylhexosaminidase is a primer of platelet activation
Emmerich J. - Bilateral deep-vein thrombosis and cancer: prospective study of 103 patients
  - Tissue Factor-603 A–G promoter polymorphism is associated with human monocyte constitutive but not with LPS induced gene expression
Emmerich J. - Asymptomatic venous thrombosis is a frequent event in protein C deficiency: a systematic ultrasound assessment of 208 family members with the 3363-C insertion mutation (IPCI: International Protein C Investigation)
Emmerich J. - Factor II 20210 G-A but not Factor V Arg506Gln gene polymorphism is associated with peripheral arterial disease in a case-control study
  - Quality of life and risk perception in a large family with heritable protein C deficiency (IPCI: International Protein C Investigation)
Emsley J. - Structure of the Glycoprotein Ib N-terminal domain
  - Structure of the platelet glycoprotein Iba N-terminal domain
Emsley J. - Crystal structure at 1.7 A of aggretin, a heterodimeric C-type lectin snake venom protein
Enayat M. S. - A common mutation 4247T ® A (I1416N) causing type 2M von Willebrand disease in patients from three unrelated families previously diagnosed as severe type 1 VWD
  - Identification of six novel mutations in families with type 3 von Willebrand disease
  - Identification of intron 1 and 22 inversion mutation in the factor VIII gene of 94 Iranian families with hemophilia A
Enayat S. - Mutation analysis in type 1 von Willebrand disease patients entered in the multicenter MCMDM-1VWD study
Enayat M. S. - Identification of factor IX mutations in 17 Iranian families with hemophilia B
Enayat M. S. - Are there really undetectable Factor VIII mutations in hemophilia A? How can we deal with the difficult ones?
  - Inherited and de novo von Willebrand disease ‘Vicenza’ in UK families with the R1205H mutation
Enayat M. S. - Two candidate type 2 M von Willebrand disease mutations in two unrelated families with unusual phenotypes
Enayat M. S. - Compound heterozygous Protein C deficiency resulting in neonatal purpura fulminans: identification of a novel mutation and its functional consequences
  - Evaluation of a protein truncation test (PTT) for mutation detection in von Willebrand disease
Enciso J. - Matrix, protease and angiogenesis
Endler G. - A microsatellite polymorphism in the Heme Oxygenase – 1 gene promoter is associated with increased serum bilirubin and HDl levels but not with a decreased risk for coronary artery disease
Endler G. - Impact of platelet glycoprotein Ibalpha Kozak polymorphism on risk of ischemic cerebrovascular events
  - Variation in plasminogen activator inhibitor-1 gene and risk of meningococcal disease
Endres J. L. - A case of compound type 2N/type 1 von Willebrand disease linked to a novel von Willebrand factor exon 18 mutation A2311G encoding for Met 771 val
Engel Hardt W. - Evaluation of an automated von Willebrand factor (vWF) antigen assay
Engelhardt W. - Performance of a new PT Calibrator
Engelhardt W. - Comparative evaluation of a new automated latex agglutination d-dimer assay for exclusion of deep vein thrombosis
Engelmann B. - Microvesicle and platelet associated tissue factor promote initiation of coagulation
Engelmann L. - Platelet mediated thrombin generation depends on F VIII and Factor IX in a complex way: evidences for the Cell-based model of hemostasis
  - The influence of the prothrombin mutation 20210 GA and the level of prothrombin on the thrombin generation
  - GP IIb-IIIa antagonists and thrombin generation
Englyst N. A. - Reduced sensitivity to aPC after fish oil supplementation via increased LDL and platelet microparticle formation
Engova D. - Multivariate investigation of determinants of oral anti-coagulant stability
Enjolras N. - Human factor IX expression in megakaryocytes derived from electrophorated human hematopoietic cells
Entezari V. - Prevalence of activated protein C – resistance (APC-R) in patients with thromboembolic events: the first report from Iran
Epinat M. - A meta-analysis on the benefit-to-risk ratio of Vitamin K antagonists (VKA) in the prevention of venous thromboembolism in major orthopedic surgery
  - Factors predicting venous thrombotic complications after superficial–vein thrombosis
  - Differences between predictive factors for PE and DVT recurrences: results from 5 randomized trials
Epple G. - Recombinant PrPP102L stimulates t-PA mediated plasminogen activation 4-fold stronger than recombinant wild-type PrPc
Erb C. - Expression of Plasminogen activator inhibitor-1 (PAI-1) mRNA in human ciliary processes and determination of PAI-1 in human aqueous humor
Erbe M. - The German thrombophilia-registry – first results: Women specific risk factors and venous thrombosis
Erhardt J. - Potentiation of aggregation through the stimulation of platelet P2X1 receptors
Erhardtsen E. - Pharmacokinetics, pharmacodynamics and tolerability of single injections of activated recombinant FVII (rFVIIa, NovoSeven®) in healthy Caucasian and Japanese subjects
Erickson J. - Role of platelet-leukocyte–endothelium interactions in neointimal hyperplasia
Eriksen M. - Localized short-term myocardial ischemia causes massive coronary t-PA release
Eriksson B. I. - Absence of transaminase increase after 4-week administration of fondaparinux (Arixtra®), a new synthetic and selective inhibitor of factor Xa, in the PENTHIFRA-PLUS study
Eriksson U. - Ximelagatran, the first oral direct thrombin inhibitor
Eriksson H. - Innovation in the treatment of venous thromboembolism
Eriksson B. - Best practices in Orthopedic surgery
Eriksson B. I. - Pharmacokinetics of BIBR 953 ZW, the active form of the oral direct thrombin inhibitor BIBR 1048, in patients undergoing hip replacement
  - The effect of BIBR 953 ZW, the active form of the oral direct thrombin inhibitor BIBR 1048, on the prolongation of aPTT and ECT in orthopedic patients: a population pharmacodynamic study
Eriksson P. - Influence of intraluminal thrombus on cellular and structural features of the aneurysm wall
Eriksson B. I. - No episode of thrombocytopenia after four-week administration of fondaparinux, a new synthetic and selective inhibitor of factor Xa, in the PENTHIFRA-PLUS study
  - Consistency of efficacy of extended thromboprophylaxis with fondaparinux (Arixtra) in prevention of venous thromboembolism (VTE) after hip fracture surgery according to different composite efficacy endpoints: the PENTHIFRA-PLUS study
Eriksson B. I. - Efficacy and safety of the treatment regimen of melagatran and ximelagatran for prevention of thromboembolic events after total hip or knee replacement: a meta-analysis of 3 randomized, double-blind studies, to evaluate the influence of time and dose
Eriksson U. G. - No influence of alcohol intake on the pharmacokinetics or pharmacodynamics of the oral direct thrombin inhibitor, ximelagatran, in healthy volunteers
Eriksson B. I. - Relevance of venographic distal thrombus assessment in venous thromboembolism (VTE) prophylaxis studies: lessons from the fondaparinux (Arixtra®) database in major orthopedic surgery
Eriksson B. - Influence of the duration of fondaparinux prophylaxis in preventing venous thromboembolism (VTE) following major orthopedic surgery
Eriksson U. G. - Excretion of the oral direct thrombin inhibitor ximelagatran into breast milk following oral administration to breast-feeding women
Eriksson B. I. - Efficacy of fondaparinux (Arixtra) in extended thromboprophylaxis in hip fracture surgery is irrespective of patient and surgical characteristics: subgroup analyses of the Penthifra-Plus study
Eriksson B. - Evaluating bleeding complications of thromboprophylaxis after hip replacement: a systematic review
Eriksson B. I. - Persistence of the risk of venous thromboembolism (VTE) for at least four weeks after hip fracture surgery: evidence from the fondaparinux hip fracture surgery database
Eriksson H. - Extended secondary prevention with the oral direct thrombin inhibitor ximelagatran for 18 months after 6 months of anticoagulation in patients with venous thromboembolism: a randomized, placebo-controlled trial
Erlich J. - The cytoplasmic domain of tissue factor contributes to leukocyte recruitment and death in endotoxemia
Erlinge D. - Quantification of ADP and ATP receptor expression in human platelets
  - Increase in mitogenic and decrease in contractile P2 receptors in smooth muscle cells by fluid shear stress in intact human conduit vessels
Errico M. - Endothelial nitric oxide synthase gene variation and hypertension in pregnancy
Ertl G. - Inhibition of platelet activation in congestive heart failure by selective aldosterone receptor antagonism and angiotensin-converting enzyme inhibition – role of platelet VASP phosphorylation
  - Novel role for the membrane-bound chemokine fractalkine as a pathophysiologically relevant mechanism in platelet activation and adhesion
Erusalimsky J. - Expression of prion protein (PrPC) in the megakaryocyte lineage
Erwig L. P. - The phagocytic capacity of human endothelial cells in culture for apoptotic endothelial cells is inhibited by IgG from patients with anti-phospholipid antibodies
Escheverria A. - TNF-alpha promoter polymorphisms (-238 and -308) in patients with cerebrovascular disease
Eschwege V. - Increased factor V level and preanalytical coagulation
  - Importance of beta-2 glycoprotein I in the lupus anticoagulant cofactor effect: a case report
Escobar M. - Congenital factor VII deficiency and thrombosis. Description of a novel mutation
  - Mutation analysis and HLA genotype in patients with inhibitors and hemophilia A
Escolar G. - Bleeding due to platelet disorders - and treatment: Mechanism of action of rFVlla in quantitive and qualitive disorders of platelent function
  - Effect of antiphospholipid antibodies in the activation of the contact complex: importance in the obstetric complications of the antipospholipid syndrome
  - Hemostatic effect of activated recombinant factor VII (rFVIIa) in liver disease: studies in an in vitro model
  - Stored platelets contain residual amounts of tissue factor
  - Granulocyte colony-stimulating factor exerts a pro-inflammatory effect on endothelial cells through activation of p38 MAPK
Escurila-Ettingshausen C. - Successful immune tolerance therapy in hemophilia B patients with fix: a new immunesuppressive strategy
Escuriola Ettingshausen C. - A new protocol for inhibitor elimination in high responding hemophilia A patients
Escuriola Ettingshausen C. - Long-term prophylaxis with FEIBA® in patients with high-responding inhibitors
Escuriola-Ettinghausen C. - The development of inhibitors directed against factor VIII after continuous infusion of factor VIII concentrates in patients with hemophilia A
Esheverria A. - Hypercoagulability in cerebrovascular disease (CD): factor V Leiden, prothrombin G20210A and MTHFR C677T mutations and polymorphism in the annexin V kozac sequence
Eskaraev R. - FXIII promotes endothelial cell migration, proliferation, and inhibits apoptosis
  - Prevalence of circulating procoagulant microparticles in allogeneic stem cell transplantation (alloSCT) for hemato-oncological malignancies
Eskilson C. - Efficacy and safety of the treatment regimen of melagatran and ximelagatran for prevention of thromboembolic events after total hip or knee replacement: a meta-analysis of 3 randomized, double-blind studies, to evaluate the influence of time and dose
Eskola M. - Relation of prothrombotic platelet polymorphisms to the first manifestation of Coronary Artery Disease in middle-aged males
Eslin D. E. - A transgenic mouse model demonstrates the efficacy of Factor VIII ectopically expressed in platelets for Haemophilia A treatment
  - A novel platelet-specific delivery system for fibrinolytic agents
Eslin D. E. - Transgenic mice studies demonstrate a role for platelet factor 4 (PF4) in thrombosis: implications for heparin-induced thrombocytopenia (HIT)
Esmon C. T. - Inflammation and thrombosis - Collen Foundation Lecture
Esmon C. T. - The molecular basis of thrombin allostery revealed by a 1.8-Å structure of the ‘slow’ form
  - Prognostic value of activated protein C levels in patients with severe sepsis
España F. - The 4678G/C polymorphism in the endothelial protein C receptor (EPCR) gene is associated with levels of soluble plasma EPCR
España F. - Circulating activated protein C in Behcet's disease and risk of thrombosis
España F. - Quantitative real-time gene expression analysis for several components of fibrinolytic and matrix metalloproteinase systems in primary breast cancer
  - Quantitative real-time reverse transcription-PCR (RT-PCR) assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1 and tissue metalloproteinase inhibitor type 1 gene expression and protein levels in endometriosis
  - Lipoprotein (a) levels and isoforms and fibrinolytic parameters in young survivors of myocardial infarction with and without peripheral artery disease
  - The 4678G/C polymorphism in the endothelial protein C receptor (EPCR) gene reduces the risk of venous thromboembolism in carriers of the factor V Leiden mutation
Español I. - Transmission electron microscopy of granulocyte inclusions in genetically confirmed MYH9-related disorders
Espana F. - Synergy between deficiencies of plasma glucosylceramide and deficiency of activated protein C for venous thromboembolism
Espeldegui T. - Retrospective analysis of heritable thrombophilia in 90 children with Legg-Perthes disease
Espindle A. - Role of platelet-leukocyte–endothelium interactions in neointimal hyperplasia
Espinós C. - Detection the 3614 G > A (R1205H) mutation in the VWF gene in 26 Spanish patients with high penetrance dominant type 1 von Willebrand disease
Espinosa G. - Effect of antiphospholipid antibodies in the activation of the contact complex: importance in the obstetric complications of the antipospholipid syndrome
  - Polymorphisms of platelet glycoproteins Ib-a and Ia/IIa: relationship with early arteriosclerosis and arterial thrombosis in patients with the antiphospholipid syndrome or with systemic lupus erythematosus
Espinosa-Parrilla Y. - PROS1 mutations that introduce a premature termination codon explain protein S deficiency by nonsense-mediated mRNA decay
Espinoza J. - Retrospective analysis of heritable thrombophilia in 90 children with Legg-Perthes disease
Essayagh S. - Shedding of active tissue factor (TF) by rat aortic smooth muscle cells (SMCs) undergoing apoptosis
Essouri S. - Fatal intra cerebral hemorrhage due to severe vitamin K deficiency disclosing cystic fibrosis
Estaki B. - Hemophilia as a model for analysis of human germ-line mutagenesis: frequent mosacism and low male to female sex ratio for G:C®A:T nonCpG transitions and the first observation of a nucleotide bi-mutation are consistent with effects in early embryogenesis
Estellés A. - Quantitative real-time reverse transcription-PCR (RT-PCR) assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1 and tissue metalloproteinase inhibitor type 1 gene expression and protein levels in endometriosis
Estelles A. - Quantitative real-time reverse transcription-PCR (RT-PCR) assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1 and tissue metalloproteinase inhibitor type 1 gene expression and protein levels in endometriosis
Estellés A. - The 4678G/C polymorphism in the endothelial protein C receptor (EPCR) gene reduces the risk of venous thromboembolism in carriers of the factor V Leiden mutation
Estellés A. - Lipoprotein (a) levels and isoforms and fibrinolytic parameters in young survivors of myocardial infarction with and without peripheral artery disease
Estellés A. - The 4678G/C polymorphism in the endothelial protein C receptor (EPCR) gene is associated with levels of soluble plasma EPCR
  - Quantitative real-time gene expression analysis for several components of fibrinolytic and matrix metalloproteinase systems in primary breast cancer
  - Circulating activated protein C in Behcet's disease and risk of thrombosis
Etro D. - Heterogeneous molecular pattern of Factor VII deficiency associated to cerebral hemorrhage
Etscheid M. - Mechanisms involved in the differential regulation of endothelial cells and lung fibroblasts by the hyaluronan-binding protease
Etscheid M. - Intracellular signaling in human endothelial cells induced by the hyaluronan-binding protease
Ettelaie C. - Investigations on the regulation of vascular smooth muscle cell migration by tissue factor (CD142)
  - The influence of tissue factor (CD142) on endothelial cell apoptosis and proliferation
Ettema H. B. - Day-care or short-stay surgery and venous thromboemolism: an overview
Eulmeskian P. - Poor correlation between aPTT, anti-Xa levels and heparin dose in children receiving therapeutic doses of unfractionated heparin
Eun Sook L. - Circulating vascular cell adhesion molecule-1 in patients with operable breast cancer
Evangelista V. - Injection of the inflammatory peptide fMLP in the rabbit induces transient myocardial ischemia: role of thromboxane A2
  - SRC-dependent signaling is a key step in the process of autoregulation of Mac-1 adhesive function in human PMN
Evangelista V. - Beta-2 integrin adhesion triggered by E-selectin in human PMN: role of SRC kinases and of an unidentified receptor
Evangelisti L. - Optimization of human 14 000 oligonucleotide-microarrays and study design for the evaluation of gene expression profiling in cardiovascular diseases
  - Assessment of platelet function during cardiopulmonary bypass using two new "point of care" devices
Evans M. A. - Economic evaluation of anti-D immunoglobulin in the treatment of immune thrombocytopenic purpura in adults in the United Kingdom
Evans C. - Development of economic and outcomes model of hemophilia treatment in Latin America and South-east Asia
Evans R. - A key role of the fast ATP-gated P2X1 cation channel in the thrombosis of small arteries in vivo
Evans M. A. - Economic modeling of full-length anti-hemophilic factor (recombinant), plasma/albumin-free method (rAHF-PFM), vs. B-domain deleted rFVIII (BDDrFVIII) in previously treated patients (PTPs) with hemophilia A
Evans R. - A key role of the fast ATP-gated P2 X 1 cation channel in the thrombosis of small arteries in vivo
Evans G. - Measurement of the in-vitro half life and the pathological significance of the transition of anti-thrombin to the latent state
Evans R. - The role of the P2Y1, P2Y12, and P2X1 platelet receptors in a laser-induced model of arterial thrombosis in vivo
Evatt B. L. - Relationship of the Val34Leu polymorphism in the factor XIII gene with venous thromboembolism in American whites and blacks: the GATE study
  - The relationship between genetic variants in peroxisome proliferator-activated receptors and venous thromboembolism in African-Americans and Caucasians
  - Heart disease among males with hemophilia
Evatt B. - Treatment and management of women with bleeding disorders and menorrhagia (WBDM) study: study design and characteristics of women enrolled
Evatt B. L. - Association of plasma homocysteine, serum folate, and red-blood cell folate with venous thromboembolism in American whites and blacks: the GATE study
  - Renal disease among persons with hemophilia
Everington T. - Reduction in stillbirth and IUGR with aspirin +/- low molecular weight heparin treatment in pregnancy
Ewenstein B. - Designing an advanced category rFVIII concentrate
  - Continuing clinical evaluation of an advanced category recombinant FVIII, antihemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM) in previously treated patients (PTPs)
  - Clinical evaluation of an advanced category recombinant FVIII, anti-hemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM) in pediatric previously treated patients (PTPs)
  - Clinical evaluation of an advanced category recombinant FVIII, anti-hemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM) in surgical settings
  - Economic modeling of full-length anti-hemophilic factor (recombinant), plasma/albumin-free method (rAHF-PFM), vs. B-domain deleted rFVIII (BDDrFVIII) in previously treated patients (PTPs) with hemophilia A
Exadaktylos N. - C-reactive protein: a link between inflammation and thrombosis formation in patients with unstable angina?
Exner T. - Laboratory diagnosis of congenital thrombophilia: current and past practice in Australia
Exner T. - Procoagulant phospholipid in blood normally associates mainly with cells or aggregates larger than microparticles or platelets
Exner T. - Laboratory assessment of acquired thrombophilia: current and past experience in Australasia with lupus anticoagulant (LA) and anti-cardiolipin antibody (ACA) testing
Exner M. - A microsatellite polymorphism in the Heme Oxygenase – 1 gene promoter is associated with increased serum bilirubin and HDl levels but not with a decreased risk for coronary artery disease
Exner T. - Detection of procoagulants with a more reliable nonactivated clotting test
Eybrechts K. L. - IRS-1 mediates platelet inhibition by insulin via the inhibitory G-protein Gi